TY - JOUR
T1 - Large decreases in standardized uptake values after definitive radiation are associated with better survival of patients with locally advanced non-small cell lung cancer
AU - Lopez Guerra, Jose L.
AU - Gladish, Gregory
AU - Komaki, Ritsuko
AU - Gomez, Daniel
AU - Zhuang, Yan
AU - Liao, Zhongxing
PY - 2012/2/1
Y1 - 2012/2/1
N2 - We evaluated potential associations between maximum standardized uptake value (SUV max) on 18F-FDG PET before and after radiation therapy (RT) and survival outcomes for patients with locally advanced non-small cell lung cancer. Methods: Patients with stage III non-small cell lung cancer (n = 49) who had undergone 18F-FDG PET at the M.D. Anderson Cancer Center both before and up to 3.5 mo after undergoing radiochemotherapy were studied; exclusion criteria were patients with a history of thoracic surgery, RT, or other cancer or those who had received a total radiation dose less than 60 Gy. We assessed associations between overall survival (OS) or disease-free survival (DFS) and post-RT SUV max and the extent of decrease in SUV max in the primary tumor (PT) and regional lymph nodes (LNs). SUV max was assessed as a continuous variable by Cox proportional hazards regression analysis. Results: Univariate and multivariate analyses showed that having a high post-RT SUV max (either PT or LNs) was associated with a higher risk of death (univariate analyses: hazard ratio [HR] for PT SUV max, 1.27, P < 0.0001; HR for LN SUV max, 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV max, 1.16, P = 0.004; HR for LN SUV max, 1.32, P = 0.001). Moreover, after definitive RT, the greater the decrease in SUV max in the lesion that had the highest SUV max at diagnosis, the longer the OS (HR, 0.06; P = 0.002), DFS (HR, 0.03; P = 0.001), local-regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028). Conclusion: The post-RT SUV max in both the PT and the LNs was a predictor of survival - specifically, the higher the residual SUV max after RT, the poorer the OS and DFS; and the greater the decrease in SUV max in the lesion with the highest SUV max at diagnosis, the longer the OS and DFS. This information should help to identify patients who are at high risk of recurrence and for whom additional treatments can be designed accordingly.
AB - We evaluated potential associations between maximum standardized uptake value (SUV max) on 18F-FDG PET before and after radiation therapy (RT) and survival outcomes for patients with locally advanced non-small cell lung cancer. Methods: Patients with stage III non-small cell lung cancer (n = 49) who had undergone 18F-FDG PET at the M.D. Anderson Cancer Center both before and up to 3.5 mo after undergoing radiochemotherapy were studied; exclusion criteria were patients with a history of thoracic surgery, RT, or other cancer or those who had received a total radiation dose less than 60 Gy. We assessed associations between overall survival (OS) or disease-free survival (DFS) and post-RT SUV max and the extent of decrease in SUV max in the primary tumor (PT) and regional lymph nodes (LNs). SUV max was assessed as a continuous variable by Cox proportional hazards regression analysis. Results: Univariate and multivariate analyses showed that having a high post-RT SUV max (either PT or LNs) was associated with a higher risk of death (univariate analyses: hazard ratio [HR] for PT SUV max, 1.27, P < 0.0001; HR for LN SUV max, 1.32, P = 0.004) and disease recurrence (univariate analyses: HR for PT SUV max, 1.16, P = 0.004; HR for LN SUV max, 1.32, P = 0.001). Moreover, after definitive RT, the greater the decrease in SUV max in the lesion that had the highest SUV max at diagnosis, the longer the OS (HR, 0.06; P = 0.002), DFS (HR, 0.03; P = 0.001), local-regional control (HR, 0.04; P = 0.002), and distant metastasis-free survival (HR, 0.07; P = 0.028). Conclusion: The post-RT SUV max in both the PT and the LNs was a predictor of survival - specifically, the higher the residual SUV max after RT, the poorer the OS and DFS; and the greater the decrease in SUV max in the lesion with the highest SUV max at diagnosis, the longer the OS and DFS. This information should help to identify patients who are at high risk of recurrence and for whom additional treatments can be designed accordingly.
KW - Chemoradiation therapy
KW - Non-small cell lung cancer
KW - Positron emission tomography
KW - Radiation therapy
KW - Standardized uptake value
UR - http://www.scopus.com/inward/record.url?scp=84856796821&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84856796821&partnerID=8YFLogxK
U2 - 10.2967/jnumed.111.096305
DO - 10.2967/jnumed.111.096305
M3 - Article
C2 - 22241911
AN - SCOPUS:84856796821
SN - 0161-5505
VL - 53
SP - 225
EP - 233
JO - Journal of Nuclear Medicine
JF - Journal of Nuclear Medicine
IS - 2
ER -